Endocrinology
Partner With Us
Advertisement
Conexiant chevron_right Endocrinology chevron_right Ecnoglutide Shows Strong Weight Loss in Trial
From the Journals Conference News ADA's 85th Scientific Sessions

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant
Full Article Summary Notecard
  1. Ecnoglutide is a glucagon-like peptide-1 receptor agonist for obesity treatment.
  2. Phase 3 trial involved 664 adults with overweight or obesity without diabetes.
  3. 2.4 mg dose led to 15.4% weight reduction over 48 weeks.
  4. Mild gastrointestinal side effects declined over time.
  5. Significant improvements in metabolic health indicators were observed.
  6. 93% achieved at least 5% weight loss. 7. Future studies needed for broader population applicability.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.